" class="no-js "lang="en-US"> Astellas Pharma Archives - Medtech Alert
Saturday, September 30, 2023

Sort by:


Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

FDA Grants Accelerated Approval for PADCEV® with KEYTRUDA for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer

Seagen and Astellas Pharma have announced the United States Food and Drug Administration (FDA) has […]

MIMETAS and Astellas Enter into Strategic Partnership

MIMETAS, a global leader in human disease modeling, announces that it has entered into a […]

Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer

Pfizer and Astellas Pharma have announced positive topline results from the Phase 3 EMBARK trial […]

Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib

Astellas Pharma and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) today announced […]

Astellas Provides Update on Fezolinetant New Drug Application in U.S.

Astellas Pharma has announced the US Food and Drug Administration (FDA) notified the company that […]

Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and GO Therapeutics, Inc. (Co-Founder […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more